Charles River Laboratories

Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy Programs

WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 10, 2022-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its nAAVigation™ Vector Platform (nAAVigation). Leveraging decades of Adeno-Associated Virus (AAV) vector contract development and manufacturing (CDMO) experience and biologics testing expertise, Charles River has established a platform which streamlines the pathway to GMP AAV vector manufacturing without...
Wilmington, Massachusetts

888.319.5343